Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sickness fund begins disease management project:

This article was originally published in Clinica

Executive Summary

Germany's largest statutory health insurance fund, the AOK, is preparing a series of new projects designed to aid in the treatment of the chronically ill. The initiative fits in with the government's desire to reform the Risikostrukturausgleich, the fund balancing mechanism, but, as Dr Gabriele Muller de Cornejo of the AOK explains, has been long overdue. "We have an outstanding system for acute care in Germany, but chronic care is unbelievably poorly organised," she says. The Disease Management system which the AOK hopes to introduce, would better co-ordinate prevention, diagnosis, therapy, rehabilitation and care. It would further ensure that doctors, care services, hospitals and rehabilitation services are kept in constant communication with one another.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT072192

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel